/First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
Citation Map
The articles shown here are a subset.See the full list of articles below.
Citing (0)
Citation Count
Data not found
Cited By (0)
Citation Count